These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24351008)

  • 1. Regulating cell-based regenerative medicine: the challenges ahead.
    Ali RR; Hollander AP; Kemp P; Webster A; Wilkins MR
    Regen Med; 2014 Jan; 9(1):81-7. PubMed ID: 24351008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in regenerative medicine strategies for cancer treatment.
    Mansouri V; Beheshtizadeh N; Gharibshahian M; Sabouri L; Varzandeh M; Rezaei N
    Biomed Pharmacother; 2021 Sep; 141():111875. PubMed ID: 34229250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product.
    Fujiwara Y; Maruyama Y; Honda F
    Clin Pharmacol Ther; 2021 May; 109(5):1182-1185. PubMed ID: 32979224
    [No Abstract]   [Full Text] [Related]  

  • 4. Cell Therapy Regulatory Toolkit: an online regulatory resource.
    Culme-Seymour EJ; Davies JL; Hitchcock J; Mason J; Carpenter MK; Mason C
    Regen Med; 2015; 10(5):531-4. PubMed ID: 26237697
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging Translation of Regenerative Therapies.
    Allickson JG
    Clin Pharmacol Ther; 2017 Jan; 101(1):28-30. PubMed ID: 27806427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protecting methods for treatment related to regenerative medicine and gene therapy in Japan.
    Kaneshiro K; Masuda S; Tanaka Y; Tamai K
    Nat Biotechnol; 2004 Mar; 22(3):343-5. PubMed ID: 14990960
    [No Abstract]   [Full Text] [Related]  

  • 7. Cell and gene therapy manufacturing capabilities in Australia and New Zealand.
    O'Sullivan GM; Velickovic ZM; Keir MW; Macpherson JL; Rasko JEJ
    Cytotherapy; 2019 Dec; 21(12):1258-1273. PubMed ID: 31806531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of cell-based therapies in Europe: current challenges and emerging issues.
    Blasimme A; Rial-Sebbag E
    Stem Cells Dev; 2013 Dec; 22 Suppl 1(Suppl 1):14-9. PubMed ID: 24304069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparing regenerative therapies for clinical application: proposals for responsible translation.
    Shapiro SA; Smith CG; Arthurs JR; Master Z
    Regen Med; 2019 Feb; 14(2):77-84. PubMed ID: 30651044
    [No Abstract]   [Full Text] [Related]  

  • 10. Organizational profile: UK regenerative medicine platform immunomodulation hub.
    Asante CO
    Regen Med; 2015; 10(3):259-63. PubMed ID: 25933235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada.
    Roy DC; Alarco AM; Isasi R
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():24-8. PubMed ID: 25457957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regenerative medicine: future impact on clinical therapies and society.
    Kargul J; Laurent GJ; Irminger-Finger I
    Int J Biochem Cell Biol; 2014 Nov; 56():1. PubMed ID: 25461768
    [No Abstract]   [Full Text] [Related]  

  • 14. Corporate profile: RoosterBio, Inc.
    Olsen TR; Rowley JA
    Regen Med; 2018 Oct; 13(7):753-757. PubMed ID: 30289343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming healthcare through regenerative medicine.
    Jessop ZM; Al-Sabah A; Francis WR; Whitaker IS
    BMC Med; 2016 Aug; 14(1):115. PubMed ID: 27510095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
    Rose JB; Williams DJ
    Regen Med; 2012 May; 7(3):429-38. PubMed ID: 22594333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.
    Ciccocioppo R; Dos Santos CC; Baumgart DC; Cangemi GC; Cardinale V; Ciacci C; De Coppi P; Haldar D; Klersy C; Nostro MC; Ott M; Piemonti L; Tomei AA; Uygun B; Vetrano S; Orlando G
    Cytotherapy; 2018 Mar; 20(3):461-476. PubMed ID: 29398624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implications of "advanced therapies" regulation.
    Sethe SC
    Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The advancement of human pluripotent stem cell-derived therapies into the clinic.
    Thies RS; Murry CE
    Development; 2015 Sep; 142(18):3077-84. PubMed ID: 26395136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.